Melanie Ayala Ceja

Melanie Ayala Ceja

Auto-generated profile, based on publicly available information

Melanie Ayala Ceja

Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MCMelanie Ayala Ceja
Melanie Ayala Ceja
MKMobina Khericha
Mobina Khericha
CHCaitlin M. Harris
Caitlin M. Harris
CPCristina Puig-Saus
Cristina Puig-Saus
YCYvonne Y. Chen
Yvonne Y. Chen
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.

23 November 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SLSarah M. Larson
Sarah M. Larson
CWChristopher M. Walthers
Christopher M. Walthers
BJBrenda Ji
Brenda Ji
SGSanaz N. Ghafouri
Sanaz N. Ghafouri
JNJacob Naparstek
Jacob Naparstek
YCYvonne Y. Chen
Yvonne Y. Chen
To address antigen escape and loss of T-cell functionality, we report a phase I clinical trial (NCT04007029) evaluating autologous naive and memory T (TN/MEM) cells engineered to express a bispecific anti-CD19/CD20 chimeric antigen receptor (CAR; CART19/20) for patients with relapsed/refractory non-Hodgkin lymphoma (NHL), with safety as the primary endpoint. Ten patients were treated with 36 × 106 to 165 × 106 CART19/20 cells. No patient experienced neurotoxicity of any grade or over grade 1 cytokine release syndrome. One case of dose-limiting toxicity (persistent cytopenia) was observed. Nine of 10 patients achieved objective response [90% overall response rate (ORR)], with seven achieving complete remission [70% complete responses (CR) rate]. One patient relapsed after 18 months in CR but returned to CR after receiving a second dose of CART19/20 cells. Median progression-free survival was 18 months and median overall survival was not reached with a 17-month median follow-up. In conclusion, CART19/20 TN/MEM cells are safe and effective in patients with relapsed/refractory NHL, with durable responses achieved at low dosage levels. Significance: Autologous CD19/CD20 bispecific CAR-T cell therapy generated from TN/MEM cells for patients with NHL is safe (no neurotoxicity, maximum grade 1 cytokine release syndrome) and demonstrates strong efficacy (90% ORR, 70% CR rate) in a first-in-human, phase I dose-escalation trial. This article is highlighted in the In This Issue feature, p. 517

12 April 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MLMeng-Yin Lin
Meng-Yin Lin
ENEunwoo Nam
Eunwoo Nam
RSRyan M. Shih
Ryan M. Shih
ASAmanda Shafer
Amanda Shafer
ABAmber Bouren
Amber Bouren
YCYvonne Y. Chen
Yvonne Y. Chen
Cytokine release syndrome (CRS) is a frequently observed side effect of chimeric antigen receptor (CAR)-T cell therapy. Here, we report self-regulating T cells that reduce CRS severity by secreting inhibitors of cytokines associated with CRS. With a humanized NSG-SGM3 mouse model, we show reduced CRS-related toxicity in mice treated with CAR-T cells secreting tocilizumab-derived single-chain variable fragment (Toci), yielding a safety profile superior to that of single-dose systemic tocilizumab administration. Unexpectedly, Toci-secreting CD19 CAR-T cells exhibit superior in vivo antitumor efficacy compared with conventional CD19 CAR-T cells. scRNA-seq analysis of immune cells recovered from tumor-bearing humanized mice revealed treatment with Toci-secreting CD19 CAR-T cells enriches for cytotoxic T cells while retaining memory T-cell phenotype, suggesting Toci secretion not only reduces toxicity but also significantly alters the overall T-cell composition. This approach of engineering T cells to self-regulate inflammatory cytokine production is a clinically compatible strategy with the potential to simultaneously enhance safety and efficacy of CAR-T cell therapy for cancer.

4 March 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
TGTorahito A. Gao
Torahito A. Gao
RSRyan M. Shih
Ryan M. Shih
JCJustin D. Clubb
Justin D. Clubb
SHShao-Hsi Hung
Shao-Hsi Hung
TSTanya Singh
Tanya Singh
YCYvonne Y. Chen
Yvonne Y. Chen
Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy against solid tumors, which often reside in highly immunosuppressive tumor microenvironments (TMEs). TMEs can be highly abundant in vascular endothelial growth factor A (VEGF), which contributes to immunosuppression and abnormal tumor vasculature. Here, we found that CAR T cells engineered to secrete an anti-VEGF single-chain variable fragment (CAR-αVEGF T cells) achieved superior antitumor efficacy against multiple in vivo models of ovarian cancer and glioma, outperforming conventional CAR T cells with and without combination anti-VEGF antibody therapy. Microscopy, flow cytometry, and transcriptomic analyses revealed that armoring the CAR T cells with anti-VEGF single-chain variable fragments enhanced their activation and mitochondrial fitness and enriched immune-stimulatory signatures among endogenous immune cells in the tumor-bearing brain. Moreover, CAR-αVEGF T cells circumvented multiple detrimental effects associated with on-target CAR T cell therapy, including infiltration of suppressive myeloid cells, exaggerated vasculature abnormalities, and hypoxia. Together, our results provide rationale for the clinical translation of CAR-αVEGF T cells as a safe and potent therapy for solid tumors characterized by elevated VEGF.

4 April 2023
Verified
Other
Open access
SLSarah M. Larson
Sarah M. Larson
CWChristopher M. Walthers
Christopher M. Walthers
BJBrenda Ji
Brenda Ji
SGSanaz N. Ghafouri
Sanaz N. Ghafouri
JNJacob Naparstek
Jacob Naparstek
YCYvonne Y. Chen
Yvonne Y. Chen
T cell populations become CD8-dominant post CART19/20 cell infusion. % CD8+ among (A) CAR-expressing T cells and (B) all CD3+ T cells was quantified by flow cytometry. Data are shown for CAR-T cells only up to day 90 post infusion as values post day 90 become unreliable due to low CAR+ cell count detected by flow. FP: final product (i.e., cryopreserved CART19/20 cells).

4 April 2023
Verified
Other
Open access
SLSarah M. Larson
Sarah M. Larson
CWChristopher M. Walthers
Christopher M. Walthers
BJBrenda Ji
Brenda Ji
SGSanaz N. Ghafouri
Sanaz N. Ghafouri
JNJacob Naparstek
Jacob Naparstek
YCYvonne Y. Chen
Yvonne Y. Chen
CART19/20 cell product characteristics. (A) % CD4+ among total T cells and CAR-expressing T cells. (B) Comparison of T-cell subtype frequency among CD4+ vs. CD8+ T cells in cryopreserved CART19/20 cell products. Te/exh: effector/exhausted T cells, CD45RA+/CD45RO–/CD62L–; Tem: effector-memory T cells, CD45RA–/CD45RO+/CD62L–; Tcm: central-memory T cells: CD45RA–/CD45RO+/CD62L+; naïve: CD45RA+/CD45RO–/CD62L+. (C) Phenotype of leukopak content prior to cell isolation. (D) Phenotype of cells obtained after isolation. (E) CD14 and CD25 expression patterns among CD62L+ cells in patient leukopak content prior to cell isolation.